サポート ブログ The Power of Computational Predictors: Antibody Developability

The Power of Computational Predictors: Antibody Developability

Biointron 2024-01-25 Read time: 4 mins
SCM.jpg
Projection of Spatial-Charge-Map (SCM) values on the Fv domain, representing viscosities. DOI: 10.1080/19420862.2015.1099773

Before the road towards clinical trials, the developability properties of therapeutic antibodies need to be evaluated. Antibody molecules are assessed for developability characteristics including aggregation, immunogenicity, pharmacokinetic clearance, viscosity, and half-life span.1 This is important to ensure a stable and efficacious drug before clinical trials.

These properties can be understood through in silico methods, such as homology modelling, docking or interface prediction. During the Lead Identification and Optimization phases these tools can help to researchers to generate three-dimensional models of the antibodies and predict or identify the key residues involved in antigen binding. Machine learning tools can also predict these properties by assessing hydrophobicity, electrostatic charge, and topology pattern interaction of the amino acid sequence.2,3 


Computational Tools

Spatial-Charge-Map (SCM) is a tool developed by Agrawal et al. (2016) that can screen monoclonal antibodies for their viscosities. SCM works by quantifying the electronegative potential patch on the Fv domain of antibodies. High viscosities, commonly found with highly concentrated antibody solutions, poses several problems to develop, manufacture, and administer the potential drug. Since the antibody sequence is a component for viscosity, this SCM tool is extremely helpful for the selection of low-viscosity antibodies.4

The therapeutic antibody profiler (TAP) is an application which compares your antibody variable domain sequence against five factors: total complementarity-determining region (CDR) length, surface hydrophobicity, asymmetry in net heavy- and light-chain surface charges, and positive charge and negative charge in the CDRs. Raybould et al. (2019) published this tool to reveal antibodies that have rare characteristics in clinical-stage mAb therapeutics.5,6 


Machine Learning Tools

Jain et al. (2017) used a random forest machine learning approach to estimate the hydrophobic chromatography (HIC) retention time directly from an antibody sequence. Quantifying hydrophobicity of a monoclonal antibody is important to assess downstream risks. The researchers successfully developed predictive models to predict the surface exposure of amino-acid side-chains in the antibody’s variable region.7

At Biointron, we are dedicated to accelerating your antibody discovery, optimization, and production needs. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects. 


References:

  1. Raybould, M.I.J., Deane, C.M. (2022). The Therapeutic Antibody Profiler for Computational Developability Assessment. In: Houen, G. (eds) Therapeutic Antibodies. Methods in Molecular Biology, vol 2313. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1450-1_5

  2. Kim, J., McFee, M., Fang, Q., Abdin, O., & Kim, P. M. (2023). Computational and artificial intelligence-based methods for antibody development. Trends in Pharmacological Sciences, 44(3), 175–189. https://doi.org/10.1016/J.TIPS.2022.12.005

  3. Mieczkowski, C., Zhang, X., Lee, D., Nguyen, K., Lv, W., Wang, Y., Zhang, Y., Way, J., & Gries, M. (2023). Blueprint for antibody biologics developability. MAbs, 15(1). https://doi.org/10.1080/19420862.2023.2185924

  4. Agrawal, N. J., Helk, B., Kumar, S., Mody, N., Sathish, H. A., Samra, H. S., Buck, P. M., Li, L., & Trout, B. L. (2016). Computational tool for the early screening of monoclonal antibodies for their viscosities. MAbs, 8(1), 43-48. https://doi.org/10.1080/19420862.2015.1099773

  5. J. Raybould, M. I., Marks, C., Krawczyk, K., Taddese, B., Nowak, J., Lewis, A. P., Bujotzek, A., Shi, J., & Deane, C. M. (2019). Five computational developability guidelines for therapeutic antibody profiling. Proceedings of the National Academy of Sciences of the United States of America, 116(10), 4025-4030. https://doi.org/10.1073/pnas.1810576116

  6. James Dunbar and others, SAbPred: a structure-based antibody prediction server, Nucleic Acids Research, Volume 44, Issue W1, 8 July 2016, Pages W474–W478, https://doi.org/10.1093/nar/gkw361

  7. Jain, T., Boland, T., Lilov, A., Burnina, I., Brown, M., Xu, Y., & Vásquez, M. (2017). Prediction of delayed retention of antibodies in hydrophobic interaction chromatography from sequence using machine learning. Bioinformatics, 33(23), 3758-3766. https://doi.org/10.1093/bioinformatics/btx519

Subscribe to our ブログ

Recent ブログ

The therapeutic efficacy of antibodies is closely related to their ability to recognize and bind specific epitopes on target antigens. Epitopes, or antigenic determinants, are a group of amino acids or other chemical groups that are part of a molecule to which an antibody attaches itself. Epitope characterization can help reveal the mechanism of antibody binding and apply intellectual property (patent) protection for novel antibodies, in addition to designing antibodies with high specificity and minimal cross-reactivity.

Jul 12, 2024
ブログ

Understanding the differences between antibody specificity and selectivity is essential for designing and interpreting antibody-based assays in research for experimental accuracy and data interpretation. Antibody specificity refers to an antibody's ability to recognize and bind to a particular epitope—a unique part of an antigen that elicits an immune response.

Jul 10, 2024
ブログ

Antibody-based assays are essential tools in biomedical research, providing the means to detect, quantify, and visualize specific proteins or antigens within complex biological samples. These assays' efficacy hinges on the antibodies' precise properties. While affinity, avidity, specificity, and selectivity are fundamental to antibody performance, the ultimate impact of these properties is heavily influenced by the experimental context in which the antibody is employed.

Jul 08, 2024
ブログ

Biologics, particularly antibodies, have become indispensable in biomedical research and therapeutic development. Research-use-only (RUO) biologics play a pivotal role in preclinical studies, providing researchers with the necessary tools to explore antibody functions and therapeutic potential in vivo.

Jul 04, 2024
ブログ

お客様の利便性を向上させるためにクッキーを使用しています。詳しくは プライバシーポリシー をご覧ください。